Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Liphello Tse Ntle ho Tsebisoa Pele Kankere ea Sebete

ngotsoeng ke mohlophisi

Helio Health, k'hamphani ea tlhokomelo ea bophelo e tsamaisoang ke AI e tsepamisitse maikutlo ho hoebisang liteko tsa tlhahlobo ea mofets'e ho tsoa ho mali a bonolo, kajeno e phatlalalitse hore Hepatology Communications e phatlalalitse liphetho tse ntle ho tsoa phuputsong ea ENCORE e netefatsang ts'ebetso e matla ea kliniki ea HelioLiver ho bona boteng ba hepatocellular carcinoma (HCC) , mofuta o tloaelehileng ka ho fetisisa oa kankere ea sebete le kankere ea bosupa e tloaelehileng lefatšeng ka bophara empa ea bobeli ho lefu le amanang le mofetše, hangata ka lebaka la ho hlahlojoa morao-rao.1 Thutong ena e neng e lebeletsoe, e foufetseng, e nang le lihlopha tse ngata tsa Phase 2, HelioLiver e bontšitse boitsebiso bo phahameng (91) %) le kutloisiso e phahameng (76%) ea ho lemoha pele-mothati (mothati oa I le oa II) HCC, e fetisang haholo lisebelisoa tse ling tse fumanehang ka kliniki tse kang AFP (57%), GALAD (65%), le ultrasound (47%). 2,3 Ha ho nahanoa ka HCC ka kakaretso, HelioLiver e ile ea sebetsa ka 85% ea kutlo ka mokhoa o tšoanang oa 91%.2           

Liteko tsa Tlhahlobo ea HCCMothati oa Pele (I + II) BoikutloBoikutlo bo akaretsang
HelioLiver276%85%
AFP (≥ 20 ng/mL)257%62%
Lintlha tsa GALAD (≥ -0.63)265%75%
Ultrasound347%84%
Tlhokomeliso: Tafole e supa maikutlo a HelioLiver ka 91% e ikhethang2
2 Lin N, le ba bang. 2021.
3 Tzartzeva K, le ba bang. 2018.

Helio e hlahisitse sethala sa eona sa tatellano ea moloko o latelang, ECLIPSETM, ho tseba sepheo sa 77 methylation ho pholletsa le liphatsa tsa lefutso tse 28. Matšoao ana a DNA a sebetsa hammoho le liprotheine tsa serum HCC AFP, AFP-L3%, le DCP ho ntlafatsa algorithm ea analyte e mengata.

• Sebaka se tlas'a sebopeho sa moamoheli (AUROC) bakeng sa HelioLiver e ne e le 0.944, e bonts'ang bokhoni ba ho tseba lintho esale pele ho feta liteko tse ling.

• Ka mokhoa o tsitsitseng oa 87.5%, HelioLiver e fihletse 87% ea kutloisiso bakeng sa HCC ea pele le 90% ea kutloisiso ka kakaretso.

• Liphatsa tsa lefutso tse 10 ho tse 28 tse sebelisitsoeng tekong ea HelioLiver li ile tsa fumanoa li ameha ka ho toba litseleng tsa limolek'hule tse tsejoang hore li ameha ho HCC pathogenesis ha e 'ngoe feela ea liphatsa tsa lefutso tsa 497 tse neng li batlisisitsoe empa e sa khethoa e ne e kopana le litekanyetso tse tšoanang, tse bontšang hore matšoao a HelioLiver a feta. e bohlokoa ho feta liteko tse sebelisang liphatsa tsa lefutso tse ling.

Hepatology Communications ke koranta ea semmuso ea phihlello e bulehileng, e hlahlobiloeng ke lithaka ea American Association for the Study of Liver Diseases (AASLD), e inehetseng ho phatlalatseng ka potlako lipatlisiso tsa boleng bo holimo tsa hepatology. AASLD ke mokhatlo o hlomphuoang ka ho fetisisa oa tataiso ea bongaka bakeng sa lefu la sebete United States.

HelioLiver e ntse e tsoela pele ho hlahlojoa e le karolo ea thuto ea bohlokoa ea Helio, e lebelloang ea ho ithuta ka biomarker, CLiMB (NCT03694600), moo ts'ebetso ea tlhahlobo e tla bapisoa ka ho toba le ultrasound e sebelisang MRI e nang le li-phasic tse ngata e le mokhoa oa tlhokomelo ea ho hlahlojoa ha HCC.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...